Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia, bipolar disorder, and serves as an adjunct therapy for major depressive disorder in adult patients.

GNH USA supplies Kventiax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is an atypical antipsychotic used across several psychiatric conditions.

Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. Bipolar disorder: stabilises mood and prevents manic or depressive episodes. Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain - Orthostatic hypotension - Dizziness

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Elevated blood glucose or new‑onset diabetes - Agranulocytosis (rare) - Hepatic enzyme elevations

Before prescribing quetiapine, clinicians should consider several safety factors.

Cardiovascular monitoring: assess blood pressure and heart rate, especially in patients with pre‑existing hypotension. Metabolic assessment: monitor weight, fasting glucose, and lipid profile regularly. Elderly patients: use lower doses and watch for increased sedation or falls. Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. Drug‑induced movement disorders: observe for signs of tardive dyskinesia or extrapyramidal symptoms. Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Quetiapine can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): can enhance sedation and respiratory depression. - Antihypertensives: additive hypotensive effect may lead to pronounced blood‑pressure drops.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine concentrations. - Anticholinergic agents: may worsen dry mouth and constipation. - Lithium: concurrent use may increase risk of neurotoxicity; monitor lithium levels.